IDP-023 Receives Fast Track Designation From FDA

The US Food and Drug Administration (FDA) has granted the Fast Track Designation to the clinical trial program for IDP-023, an allogeneic natural killer (NK) cell therapy for patients with non-Hodgkin lymphoma and multiple myeloma (MM) developed by Indapta Therapeutics, Inc.

A phase I clinical trial on IDP-023 is currently enrolling patients. Participants will receive up to three planned doses of IDP-023 with or without interleukin-2 to evaluate safety. Subsequently, patients will receive IDP-023 at recommended doses combined with either rituximab in lymphoma or daratumumab in MM.